about
Are estrogen-related drugs new alternatives for the management of osteoarthritis?New directions for drug-resistant breast cancer: the CDK4/6 inhibitorsThe Effect of Menopausal Hormone Therapies on Breast Cancer: Avoiding the RiskAre Estrogen Receptor Genomic Aberrations Predictive of Hormone Therapy Response in Breast Cancer?Trajectories and phenotypes with estrogen exposures across the lifespan: What does Goldilocks have to do with it?RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models.Selective Estrogen Receptor Modulators Suppress Hif1α Protein Accumulation in Mouse Osteoclasts.The changing role of ER in endocrine resistance.ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast CancerRunning away from side effects: physical exercise as a complementary intervention for breast cancer patients.Safety issues and adverse reactions with osteoporosis management.Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women.Effects of estrogen receptor modulators on cytoskeletal proteins in the central nervous system.Raloxifene modulates regulators of osteoclastogenesis and angiogenesis in an oestrogen deficiency periapical lesion model.Tetragonia tetragonioides (Pall.) Kuntze protects estrogen-deficient rats against disturbances of energy and glucose metabolism and decreases proinflammatory cytokines.Mouse models to evaluate the role of estrogen receptor α in skeletal maintenance and adaptation.Long-Term High-Dose Resveratrol Supplementation Reduces Bone Mass and Fracture Strength in Rats.Dangguijihwang-tang and Dangguijakyak-san Prevent Menopausal Symptoms and Dangguijihwang-tang Prevents Articular Cartilage Deterioration in Ovariectomized Obese Rats with Monoiodoacetate-Induced Osteoarthritis.New insights on the pathogenesis of endometriosis and novel non-surgical therapies
P2860
Q26746299-99FF6848-EC0A-4B9D-9697-C3D5E82FF73BQ26797396-4239A988-3F04-42F5-AA73-C3A866EE7000Q26821782-8C2D15B1-FFB1-4DCB-A168-ED3A3DA401EDQ28074060-652D140C-C2BF-4D4E-B7F4-8BBF48F10DD8Q28600847-F46A679E-89DE-4A1B-A730-654CA36EB0D0Q34484450-8BF1F06D-321A-4FAD-A652-83F61450E97CQ36179411-2249BB0E-1303-4D09-A1A1-FE1E753E1577Q36336601-6D0D3D35-70BC-4BD4-99AB-4DA1A15FC2E2Q37013898-947BE52C-971D-4013-AFE0-99418705FD9DQ37699590-D1F328E3-AF18-47C8-9781-73E39E8A452FQ38217448-604D5E09-AD41-468D-9F06-ED34508E39B3Q38677822-6E3D765C-2750-428B-ADD3-FF86E0262ED8Q38825454-7B8491CA-0F38-4ECA-A77C-8D4CD6057E35Q42361824-854DBD8A-BDF3-4890-A3CF-D117E0C98BE1Q43987138-AD0B2110-9BE7-4FEA-AC18-3F772B07FE27Q47121812-B819C6CB-3247-495F-AE02-80CC07C7FD55Q47338497-8936D837-7260-4DA1-8CE7-120373DC7EB2Q47602296-4AAB3604-952F-401E-A9D8-7610B73CF2A7Q48214541-9A9BE57E-0CDF-4A26-873A-39B5FEAA8273Q58799203-36649658-513C-4537-B9F1-94C33A14CE65
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Use of SERMs for treatment in postmenopausal women.
@ast
Use of SERMs for treatment in postmenopausal women.
@en
type
label
Use of SERMs for treatment in postmenopausal women.
@ast
Use of SERMs for treatment in postmenopausal women.
@en
prefLabel
Use of SERMs for treatment in postmenopausal women.
@ast
Use of SERMs for treatment in postmenopausal women.
@en
P1476
Use of SERMs for treatment in postmenopausal women.
@en
P2093
Joann V Pinkerton
Semara Thomas
P304
P356
10.1016/J.JSBMB.2013.12.011
P577
2013-12-25T00:00:00Z